The etiology, pathophysiology, clinical presentation, dietary management, and drug therapy of maldigestion associated with @entity3210 are reviewed. Maldigestion can occur in a number of conditions that lead to @entity3210 but is seen most frequently in @entity1 with @entity167 -related chronic @entity788 or @entity1577 . Destruction of pancreatic tissue and obstruction of the ducts that lead into the small intestine prevent pancreatic secretions from reaching the small intestine and result in @entity353 , @entity448 , @entity1661 , and changes in the appearance and frequency of stools. The goal of dietary intervention in @entity1 with maldigestion is to provide sufficient calories and protein to maintain weight while limiting fat intake to an amount tht the @entity1 can tolerate. Medium-chain @entity1674 can be substituted for dietary fat in @entity1 whose symptoms continue despite dietary fat restriction. Drug therapy involves @entity788 . Regimens must be individualized for each @entity1 because of problems with gastric inactivation of orally administered enzymes, lack of standardization of commercially available preparations, and large interpatient variation in response. In selecting an enzyme supplement preparation, the amount of available enzyme activity, dosage form, number of dosage units needed per dose, dosage schedule, and product cost must be considered. When enzyme supplementation alone does not adequately control the symptoms of maldigestion, a @entity112 H2-receptor antagonist or antacids may be added to the therapeutic regimen. Although complete resolution of the symptoms of maldigestion is difficult to achieve, a regimen of dietary modification and pancreatic-enzyme replacement can improve @entity1 ' quality of life.

Management of maldigestion associated with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis', 'supplementing deficient pancreatic enzymes with pancreatin or pancrelipase'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity1661 :: ('MESH:D000008', 'Disease') :: ['abdominal distention'] @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia'] @entity3210 :: ('MESH:D010188', 'Disease') :: ['pancreatic insufficiency'] @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine'] @entity1577 :: ('MESH:D003550', 'Disease') :: ['cystic fibrosis']
@entity3210 :: (MESH:D010188,Disease) :: ['pancreatic insufficiency']
